These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 24875463)

  • 1. Absorption, distribution, metabolism, and excretion of the novel antibacterial prodrug tedizolid phosphate.
    Ong V; Flanagan S; Fang E; Dreskin HJ; Locke JB; Bartizal K; Prokocimer P
    Drug Metab Dispos; 2014 Aug; 42(8):1275-84. PubMed ID: 24875463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics, Safety, and Tolerability of Tedizolid Phosphate After Single-dose Administration in Healthy Korean Male Subjects.
    Kim Y; Kim A; Lee S; Choi SH; Lee DY; Song JS; Lee H; Jang IJ; Yu KS
    Clin Ther; 2017 Sep; 39(9):1849-1857. PubMed ID: 28865799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens.
    Zhanel GG; Love R; Adam H; Golden A; Zelenitsky S; Schweizer F; Gorityala B; Lagacé-Wiens PR; Rubinstein E; Walkty A; Gin AS; Gilmour M; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2015 Feb; 75(3):253-70. PubMed ID: 25673021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and Safety of Tedizolid after Single and Multiple Intravenous/Oral Sequential Administrations in Healthy Chinese Subjects.
    Chen R; Shen K; Chang X; Tanaka T; Li L; Hu P
    Clin Ther; 2016 Aug; 38(8):1869-79. PubMed ID: 27461846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of tedizolid following oral administration: single and multiple dose, effect of food, and comparison of two solid forms of the prodrug.
    Flanagan SD; Bien PA; Muñoz KA; Minassian SL; Prokocimer PG
    Pharmacotherapy; 2014 Mar; 34(3):240-50. PubMed ID: 23926058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics, Safety and Tolerability of Single Oral or Intravenous Administration of 200 mg Tedizolid Phosphate in Adolescents.
    Bradley JS; Flanagan SD; Arrieta AC; Jacobs R; Capparelli E; Prokocimer P
    Pediatr Infect Dis J; 2016 Jun; 35(6):628-33. PubMed ID: 26910588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions.
    Flanagan S; Bartizal K; Minassian SL; Fang E; Prokocimer P
    Antimicrob Agents Chemother; 2013 Jul; 57(7):3060-6. PubMed ID: 23612197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and Safety of Single-dose Tedizolid Phosphate in Children 2 to <12 Years of Age.
    Arrieta AC; Ang JY; Espinosa C; Fofanov O; Tøndel C; Chou MZ; De Anda CS; Kim JY; Li D; Sabato P; Sears PS; Bradley JS
    Pediatr Infect Dis J; 2021 Apr; 40(4):317-323. PubMed ID: 33710976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial.
    Moran GJ; Fang E; Corey GR; Das AF; De Anda C; Prokocimer P
    Lancet Infect Dis; 2014 Aug; 14(8):696-705. PubMed ID: 24909499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial.
    Prokocimer P; De Anda C; Fang E; Mehra P; Das A
    JAMA; 2013 Feb; 309(6):559-69. PubMed ID: 23403680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single- and multiple-dose pharmacokinetics and absolute bioavailability of tedizolid.
    Flanagan S; Fang E; Muñoz KA; Minassian SL; Prokocimer PG
    Pharmacotherapy; 2014 Sep; 34(9):891-900. PubMed ID: 24989138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics, Safety, and Tolerability of Tedizolid Phosphate in Elderly Subjects.
    Flanagan SD; Minassian SL; Prokocimer P
    Clin Pharmacol Drug Dev; 2018 Sep; 7(7):788-794. PubMed ID: 29319932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tedizolid phosphate for the treatment of acute bacterial skin and skin structure infections.
    Gras J
    Drugs Today (Barc); 2014 Nov; 50(11):729-37. PubMed ID: 25525633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tedizolid population pharmacokinetics, exposure response, and target attainment.
    Flanagan S; Passarell J; Lu Q; Fiedler-Kelly J; Ludwig E; Prokocimer P
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6462-70. PubMed ID: 25136028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physical compatibility of tedizolid phosphate with selected i.v. drugs during simulated Y-site administration.
    Ghazi I; Hamada Y; Nicolau DP
    Am J Health Syst Pharm; 2016 Nov; 73(21):1769-1776. PubMed ID: 27769972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment.
    Flanagan S; Minassian SL; Morris D; Ponnuraj R; Marbury TC; Alcorn HW; Fang E; Prokocimer P
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6471-6. PubMed ID: 25136024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tedizolid: The First Once-Daily Oxazolidinone Class Antibiotic.
    Burdette SD; Trotman R
    Clin Infect Dis; 2015 Oct; 61(8):1315-21. PubMed ID: 26105167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of Neurologic and Ophthalmologic Safety of Oral Administration of Tedizolid for Up to 21 Days in Healthy Volunteers.
    Fang E; Muñoz KA; Prokocimer P
    Am J Ther; 2017; 24(2):e227-e233. PubMed ID: 27941424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disposition and metabolism of the new hypocholesterolemic compound S-8921 in rats and dogs.
    Yamaguchi T; Nakajima Y; Mizobuchi M; Inazawa K; Kanazu T; Kadono K; Ohkawa T; Iwatani K
    Arzneimittelforschung; 1998 Oct; 48(10):995-1006. PubMed ID: 9825117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative efficacies of tedizolid phosphate, vancomycin, and daptomycin in a rabbit model of methicillin-resistant Staphylococcus aureus endocarditis.
    Chan LC; Basuino L; Dip EC; Chambers HF
    Antimicrob Agents Chemother; 2015; 59(6):3252-6. PubMed ID: 25801564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.